Regulus Therapeutics doubles as kidney disease therapy shows promise in trial

Regulus Therapeutics

12/03/2024 14:04

(Updates)
    ** Shares of Regulus Therapeutics  RGLS.O  more than double
to a near two-year high of $2.84 
        ** Stock set for biggest one-day pct rise in nearly 10
years, if gains hold
  
    ** Co says its therapy for autosomal dominant polycystic
kidney disease (ADPKD) in an early-stage trial showed a response
in patients based on levels of polycystins in urine; polycystins
are a group of proteins that promote formation of cysts
    ** RGLS says three patients with the highest increases in
polycystins also had reductions in total kidney cyst volume
    ** ADPKD is the most common form of polycystic kidney
disease, which causes numerous cysts to grow in the kidneys, and
may lead to kidney failure
    ** Stock up 127.2% in the last 12 months 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))